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Abstract 
 
Cancer is characterised by abnormal cell proliferation and is one of the leading 
causes of death in first world countries and the second leading cause in developing 
countries. In 2012 alone, over 14 million cases were reported and over 8 million 
deaths were attributed to cancer worldwide, with sub-Saharan Africa, especially 
South Africa having one of the highest oesophageal cancer rates in the world. An 
important aspect of cancer is the telomeres, which are 10-15kbp of TTAGGG DNA 
repeats in humans at the ends of chromosomes. These repeats are maintained by the 
enzyme telomerase. Up to 90% of all cancers show increased telomerase activity to 
overcome the "end-replication" problem in which the telomeres shorten after each 
cell division. This eventually leads to cellular senescence. Due to the high number 
of cancers relying on increased telomerase activity to bypass senescence, 
telomerase could be a viable target for anti-cancer therapies. The limiting factor of 
the multi-subunit telomerase enzyme is its telomerase reverse transcriptase 
component (hTERT). hTERT has also been shown to migrate to the mitochondria 
during times of high oxidative stress caused by reactive oxygen species (ROS). 
Here it confers protection to the mitochondria against ROS, potentially preventing 
the cell form undergoing apoptosis and reaching senescence. This can potentially 
be detrimental, as cells become damaged by the ROS and continue dividing. This 
could lead to further genetic damage. Metformin, a drug used for the treatment of 
type-2 diabetes, has been linked to lower incidences of cancer. The mode of action 
of metformin is not yet fully understood, however it is known that it affects the 
mitochondria. Since hTERT and metformin could co-localise, the drug may 
influence hTERT and potentially telomerase activity. This makes metformin an 
anticancer candidate to be used in conjunction with traditional anticancer therapies.  
To determine telomerase activity in metformin treated oesophageal carcinoma cells, 
qPCR based telomerase activity assays must be used. These assays can be very 
expensive and time consuming, so a faster and cheaper alternative would be 
beneficial. Therefore, the aim of this project was to alter and improve a nanoparticle 
based detection method for telomerase activity, by decreasing the time required to 
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prepare the DNA functionalised nanoparticles as well as determining a more rapid 
method of data measurement, and compare it to conventional qPCR based 
techniques (TRAPeze RT Telomerase Activity Kit – Merck). Thereafter the effects 
of the metformin treatment on telomere dynamics, such as telomere length, 
telomerase activity and hTERT mRNA expression, in oesophageal squamous 
carcinoma cells were determined. 
Gold nanoparticles were synthesised and functionalised with thiolated-DNA 
(telomerase substrate). These functionalised particles were characterised using 
transmission electron microscopy. To assess telomerase activity the extracted 
protein was added to the functionalised nanoparticle solution and allowed to 
elongate the coupled DNA. A characteristic of gold nanoparticles is that the size of 
the particles as well as their proximity to one another determines the colour of the 
nanoparticle solution. Due to the steric hindrance caused by the now elongated 
DNA, a distinct colour change was observable. The change in absorption spectra of 
the nanoparticle solution was recorded after the enzyme elongated the substrate. 
This nanoparticle based assay was then compared to TRAPeze RT Telomerase 
detection kit (Merck-Millipore) as a positive control. Using the conventional qPCR 
based telomerase activity assay, it was found that metformin significantly decreased 
telomerase activity in oesophageal cancer cell lines, however this was not seen 
using the nanoparticle assay. A colour change was observed with the nanoparticle 
assay compared to the negative control reflecting detection of telomerase activity. 
However, no significant decrease in telomerase activity could be detected due to 
metformin treatment. 
More optimisation is required, however this technique has great potential, as 
nanoparticle based assays are also known for their high sensitivity. This technique 
is also far more rapid and significantly cheaper that the qPCR based method. The 
gold nanoparticle based telomerase activity assay could become an alternative to 
conventional qPCR based techniques. 
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1 Introduction and Literature Review: 
Using molecular biology and genetics techniques, telomere dynamics were assessed 
in metformin treated oesophageal squamous cell carcinoma cell lines. This included 
telomerase activity, human telomerase reverse transcriptase (hTERT) mRNA 
expression and telomere length. In addition, a modified telomerase activity assay, 
utilizing gold nanoparticles (AuNPs), was developed in order to find an alternative 
to conventional qPCR based methods. DNA-functionalised AuNPs were produced 
and the assay compared to the standard qPCR based telomeric repeat amplification 
protocol (TRAP). The different aspects of this project are discussed below. 
 
1.1 Oesophageal Cancer: 
Cancer is characterised by abnormal cell proliferation and is one of the leading 
causes of death in first world countries and the second leading cause in developing 
countries (Jemal et al., 2011). In 2012 alone, over 14 million cases were reported 
and over 8 million deaths were attributed to cancer worldwide, whereas in sub-
Saharan Africa over 14,000 cases were reported (Ferlay et al., 2012). Oesophageal 
cancer proved to be the 8th most common cancer, causing over 400,000 deaths 
estimated in 2012 (Ferlay et al., 2012). It has been found that southern Africa has 
an extremely high incidence rate, with South Africa in particular having the highest 
incidence rate in the world (Arnold et al., 2015). Oesophageal carcinoma is the 4th 
most diagnosed cancer for men and the 5th most prevalent cancer for woman in 
South Africa (GLOBOCAN 2012). There are two main types of oesophageal cancer 
and both have slightly different causes and are more prevalent in different parts of 
the world. The first, oesophageal adenocarcinoma, which generally presents itself 
within the lower third of the oesophagus, is more common in first world countries. 
On the other hand, oesophageal squamous cell carcinoma is more common in 
developing countries and presents itself in the upper two thirds of the oesophagus. 
There are many different risk factors for oesophageal cancer, the most common of 
which include: cigarette smoking, environmental pollutants, as well as excess 
alcohol consumption (Brown et al., 2001; Domper Arnal et al., 2015). 
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Due to the risk of metastasis in late stage oesophageal cancer, it can be difficult to 
treat if not detected early. Like for many cancers, there are three main treatment 
options available, each of which presents its own set of risks. Surgery, 
chemotherapy and radiation therapy can come with severe side effects, which can 
include diarrhoea, nausea, non-specific destruction of healthy cells as well as the 
suppression of one’s immune system (Lawenda et al., 2008). Due to these side 
effects in addition to the ineffectiveness of the treatment options at late stage 
oesophageal cancer, the importance of finding alternative therapies cannot be 
overstated. 
 
1.2 Telomeres: 
1.2.1 Structure: 
Telomeres consist of 10-15kbp of double stranded TTAGGG DNA repeats in 
humans and are found at the ends of chromosomes (reviewed in Fleming and 
Burrows, 2013). Telomeres have a 3ˊ overhang which is used to form secondary 
structures. To form structures such as the telomere loop (t-loop) (Figure 1.1), the 3ˊ 
overhang is folded back on itself. These structures in conjunction with other 
telomere stabilising proteins, including the telosome, a multi-protein structure also 
known as the “shelterin” complex (Figure 1.2), help stabilise the ends of 
chromosomes. The t-loop and the shelterin complex prevent chromosome 
degradation and fusion, in doing so regulating telomere length (Bailey and Murnane, 
2006). 
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Figure 1.1: Diagram of the Telomere Loop (t-loop). This image shows the t-loop 
fold, as well as associated binding proteins. The red strand of DNA shows the 3' 
overhang, which folds over to form the t-loop. TRF1 (blue disc) and TRF2 (dark 
green disc) are shown in conjunction with the rest of the shelterin complex to be 
stabilising the t-loop (adapted from Kovacic et al., 2011). 
 
 
 
Figure 1.2: Graphical Representation of the “Shelterin” Complex (Raffa et al., 
2013). This protein complex consists of six main proteins: RAP1, TRF1, TRF2, TIN2, 
POT1 and TPP1. Of these proteins, POT1 binds directly to single stranded telomeric DNA 
whereas TRF1 and 2 bind to double stranded telomeric DNA. The other components of the 
complex however, help stabilise and link the protein complex together (Bailey and 
Murnane, 2006). 
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1.2.2 Function: 
As previously mentioned, telomeres help stabilise the far ends of chromosomes. 
They carry out this protective function by preventing the erosion of important 
coding DNA by the “end-replication” problem (Levy et al., 1992). This loss of 
coding DNA occurs because of the incomplete synthesis of double stranded DNA, 
which is a characteristic of the mode of action of RNA dependant DNA polymerase 
(Figure 1.3). The polymerase utilises an RNA primer in order to synthesise a new 
DNA strand. A single stranded overhang remains after synthesis however, due to 
the subsequent degradation of the RNA primer (Levy et al., 1992). This overhang 
is then removed, which results in the loss of small fragments of DNA after each 
synthesis reaction (reviewed in Denchi, 2009). Therefore this leads to the 
systematic erosion of the ends of chromosomes after cell division (Blackburn, 
1991).  
 
 
Figure 1.3: Schematic Representation of the "End-Replication" Problem (Klapper 
et al., 2001). This diagram represents the DNA synthesis reaction, performed by DNA 
polymerase. Both the leading strand (green) and the lagging strand (blue) of the replication 
fork are shown with an attached RNA primer. As this RNA primer is degraded, the newly 
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synthesised double stranded DNA is missing complimentary bases on the 5ˊend, leading to 
a 3ˊ overhangs in the template strand.  
 
Telomeres act as a “buffer” zone to this erosion. If, however they are not continually 
maintained after each cell division, it will lead to the degradation of coding DNA. 
The enzyme telomerase, which is a multi-subunit protein, maintains the telomeres. 
Telomerase has been shown to be nearly undetectable in most somatic cell lines 
(Kim et al., 1994). Germ-line cells in addition to other highly proliferating cell types, 
such as intestinal and oesophageal cells, have been shown to have high telomerase 
activity. This is most likely due to these cell types requiring to undergo constant 
cell division (Kim et al., 1994; Wright et al., 1996). If the telomeres are not 
maintained and a functional DNA damage repair mechanism, such as p53, is still 
intact, it could lead to replicative senescence (where cells are metabolically active, 
but no longer replicate) or even the induction of apoptosis (programmed cell death) 
(reviewed in Shay and Wright, 2005). Taking this into consideration, DNA damage 
response pathways and telomere dynamics can play a vital role in the progression 
of diseases such as cancer, due to its characteristic uncontrolled cell proliferation 
(Figure 1.4). Normally, somatic cells are only capable of undergoing a limited 
number of cell divisions because of the shortening of telomeres. This is known as 
the “Hayflick limit” (Hayflick and Moorhead, 1961). When approaching this limit, 
it can lead to the disruption of normal tissue function, which has been theorised to 
contribute to the aging process (Sahin and Depinho, 2010; Carneiro et al., 2016). 
This is further supported by the fact that older individuals have shorter telomeres 
(Harris et al., 2012). This has led to the telomere theory of ageing. 
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Figure 1.4: Flow Diagram of Cellular Crisis. This diagram shows the relationship of 
telomere shortening in the presence and absence of functional DNA damage repair 
mechanisms (Retinoblastoma protein (pRb) and p53). In the presence of functional 
mechanisms, the cell will undergo apoptosis or replicative senescence, whereas without 
these mechanisms, telomere shortening can progress to cellular crisis. This can 
subsequently lead to genomic instability and even cancer.  
 
1.2.3 Telomeres and Cancer: 
As previously mentioned, telomeres are vital for continued cell proliferation, and 
therefore have an important role in cancer genetics. Since continued cell division 
leads to telomere shortening, DNA damage repair pathways such as the p53 
pathway can be triggered, causing cell cycle arrest (senescence) and even apoptosis 
(Shay and Wright, 2005). Consequently, senescence acts as a tumour suppressor 
mechanism, which needs to be circumvented by cells in order for them to become 
malignant (Shay and Wright, 2005). This means that if cells lack sufficient DNA 
damage responses, such as in the case of mutated p53, the cells could bypass 
senescence and become genetically unstable. This second checkpoint is known as 
“cellular crisis” (Figure 1.4). “Cellular crisis” is characterised by critically short 
telomeres and chromosome instability, which can lead to telomere fusions (Capper 
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et al., 2007). In order for cancer cells to continue proliferating at this stage, 
telomeres must either be maintained by the upregulation of telomerase (and 
therefore increased telomerase activity), or through alternative lengthening of 
telomeres (ALT) (Bryan and Reddel, 1997). ALT is recombination based and is 
utilised by approximately 10% of cancers, whereas telomerase upregulation can be 
found in up to 90% or cancers. This makes telomerase activity an interesting 
prospect for anticancer treatment (Kirkpatrick et al., 2003).  
 
1.2.4 Telomerase 
The telomerase enzyme is a ribonucleoprotein consisting of multiple subunits, two 
of which are essential. These subunits perform the main function of the enzyme, by 
maintaining telomere length. The human telomerase RNA component (hTERC) 
functions as an RNA template for the human telomerase reverse transcriptase 
component (hTERT), which adds the telomeric repeats to the ends of telomeres 
(Figure 1.5) (Carlin et al., 1997). This makes hTERT the limiting factor for enzyme 
activity (Sheng et al., 2013). It has even been shown that the increase of hTERT 
expression at any stage of the cell cycle results in the immortalisation of the cell 
line. This is further supported with the fact that hTERT mRNA levels are directly 
proportional to telomerase activity. Once again, this correlates to the high number 
of cancers (90%) that have elevated telomerase activity, as they also exhibit 
increased hTERT mRNA levels (Kirkpatrick et al., 2003).  
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Figure 1.5: Schematic Representation of the Telomerase Enzyme. This diagram 
shows how hTERT (blue) uses hTERC (red) as a template to add additional telomeric 
repeats to the ends of chromosomes.  
 
1.2.5 Regulation of hTERT mRNA Expression: 
hTERT has been described as the limiting factor of telomerase, as a change in 
hTERT expression causes a proportional change in telomerase activity (Sheng et 
al., 2013). Therefore, factors that influence hTERT mRNA expression must be 
discussed. There are multiple factors such as the variation of the hTERT 
minisatellite (MNS16A) in addition to mutations of the hTERT promoter sequence, 
which have both been associated with hTERT expression. Even specific single 
nucleotide polymorphisms (SNPs) that can be found in the hTERT promoter affect 
hTERT expression. In addition, an increased risk to lymphoblastic leukaemia and 
increased hTERT mRNA expression has been linked to the SNP rs2735940 (Sheng 
et al., 2013).  
Similarly, a genetic change in the hTERT minisatellite (MNS16A), which is a 
polymorphic tandem repeat, downstream of the hTERT gene, has been linked to 
hTERT expression. It is thought that the antisense MNS16A gene is involved in the 
silencing of hTERT mRNA. This means that the shorter variant of the minisatellite 
has an increased ability to silence hTERT mRNA. The larger variants on the other 
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hand would lead to decreased silencing, due to a decrease in antisense transcription, 
and therefore cause an increase in hTERT expression (Wang et al., 2003). Further 
supporting this; the short allele of the variable number of tandem repeats (VNTR) 
of the MNS16A minisatellite (VNTR-274) has been found to downregulate hTERT 
mRNA expression (Hofer et al., 2013). This may lead to apoptosis or even 
senescence. VNTR-274 has even had a suggested protective role against prostate 
cancer (Hofer et al., 2013). In previous research, it was also found that cell lines 
containing the larger minisatellite variant had correspondingly high telomerase 
activity (Bernert, 2014). 
Comparably the proto-oncogene, c-myc, has been shown to increase hTERT 
expression. C-myc directly targets the hTERT gene, leading to increased telomerase 
activity due to increased hTERT expression (Greenberg et al., 1999; Tang et al., 
2016). Even the p53 transcription factor has been known to target the hTERT gene. 
p53 is thought to directly bind the hTERT gene through the SP1 binding site. This 
is said to regulate hTERT expression in normal, healthy cells by decreasing hTERT 
transcription (Kanaya et al., 2000). This however means that if there should be a 
loss of function mutation in p53, that it could lead to an increase in cell division. 
 
1.2.6 hTERT and its Role in the Mitochondria: 
Recently it has recently been noted that the multi-subunit hTERT enzyme has 
multiple functions other than the elongation of telomeres. During times of oxidative 
stress, hTERT is known to relocate to the mitochondria from the nucleus. This is 
due to the presence of a targeting sequence specific to the mitochondria (Haendeler 
et al., 2009). The mitochondrial hTERT has been shown to improve mitochondrial 
function in times of oxidative stress, suggesting a potential protective role (Saretzki, 
2009). Without this form of protection, it could lead to mitochondrial dysfunction, 
which can further cause the release of reactive oxygen species (ROS). Since ROS 
are damaging to the genetic material of the cell, increased hTERT protects 
mitochondrial DNA from damage by binding to the mitochondrial DNA (Haendeler 
et al., 2009). If the effect of the ROS is severe enough, they can cause the cell to 
undergo apoptosis or enter replicative senescence. However, since hTERT confers 
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resistance to ROS, it allows the cell to avoid apoptosis and survive (Saretzki, 2009). 
Although this may enable the cell to continue functioning, it may have the 
detrimental effect of allowing the cell to continue proliferating after it has suffered 
genetic damage. This could potentially lead to “cellular crisis” or even cancer if 
certain regulatory pathways were to be affected. Studies have found that patients 
using metformin, an anti-diabetic drug which affects the mitochondria, seem to 
have lower incidences of cancer (Evans, et al., 2005). 
 
1.3 Metformin and Its Role in Cell Proliferation: 
Metformin (1,1-dimethylbiguanide hydrochloride), is an antidiabetic drug for type-
2 diabetes sufferers. The drug is known to affect the AMP-activated protein kinase 
(AMPK) pathway. This causes an increase in glucose uptake in muscle cells, which 
helps mitigate insulin resistance in type-2 diabetes sufferers (Zakikhani et al., 2006). 
LKB1, a protein kinase and an upstream regulator of the AMPK, is required by 
metformin to affect the pathway. Additionally, LKB1 has a tumour suppressor 
function (Evans et al., 2005). The activation of AMPK by metformin causes a signal 
cascade, which activates the p53 DNA damage pathway. This could indicate that 
the drug may be able to decrease cell proliferation and therefore potentially reduce 
the risk of cancer. Indeed, studies have shown that individuals using metformin 
displayed reduced cancer risk (Evans et al., 2005; Tseng, 2016). 
Additionally, it has been shown that cell proliferation in oesophageal squamous 
carcinoma cell lines is significantly reduced in the presence of metformin (Damelin 
et al., 2014). Furthermore, it was demonstrated that if mice were treated with 
metformin in conjunction with conventional chemotherapy, they experienced 
longer remission times compared to the untreated mice (Hirsch et al., 2009). 
Metformin treatment also resulted in a decreased recurrence for gastric cancer 
patients after surgery (Choong-kun et al., 2016). Considering that metformin seems 
to have an anti-proliferative effect on cancer cells, it may affect certain pathways, 
such as telomere dynamics, that are involved in cancer progression. Moreover, 
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hTERT mRNA levels have been shown to be reduced by metformin in endometrial 
cancer, however the mechanism is not yet understood (Hanna et al., 2012).  
The effects metformin has on telomerase activity in oesophageal squamous 
carcinoma cells have not yet been reported. However, our previous research showed 
a significant reduction in telomerase activity in an oesophageal cancer cell line 
expressing wild type p53. (Bernert, 2014). One possible explanation is that p53 
represses hTERT expression by acting as a transcription factor and binding the SP1 
binding sites found in the hTERT promoter. This would result in a decrease in 
hTERT expression and therefore a decrease in telomerase activity (Kanaya et al., 
2000). This could mean that a p53 mutation would render it unable to directly bind 
to the hTERT promoter, which results in an increase in telomerase activity and 
potentially helps to bring about cell immortality. Seeing that hTERT is known to 
be transported to the mitochondria, and that metformin acts within the mitochondria, 
by suppressing mitochondrial electron transport which results in the increase of the 
rate of glycolysis in a p53 dependant manner (Buzzai et al., 2007), there may be a 
direct interaction between the drug, hTERT and p53. 
 
1.4 Telomerase Activity Assays:  
Many different telomerase activity assays have been developed, these are often 
based on the telomeric repeat amplification protocol (TRAP). A TRAP protocol 
consists of a DNA telomerase substrate which is amplified by the telomerase 
enzyme in the presence of NTPs (reviewed in Zhou and Xing, 2012). After an 
extraction process, the enzyme extends the telomeric repeats on the substrate, which 
can be quantified by a quantitative polymerase chain reaction (qPCR). The number 
of repeats added is directly proportional to the signal obtained, which is then an 
accurate measurement of telomerase activity. TRAP based telomerase activity 
assays are usually reliable, however they can present many different problems. 
These protocols require whole protein extract from tissues or cells, which can leave 
impurities behind. Due to the sensitivity of the DNA binding dyes and fluorescent 
probes utilised by these protocols, these impurities, such as cell debris and genetic 
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material, can adversely affect the experiment. As with most PCR based techniques, 
non-specific binding and the formation of primer dimers can lead to false positives 
(reviewed in Zhou and Xing, 2012). qPCR based techniques are also often 
expensive and time consuming. Nanoparticles could be an answer to many of these 
problems. 
There are many different types of nanoparticles with unique and interesting 
properties. Quantum dots (QDs) for instance have been previously used to detect 
telomerase activity. One of the characteristics of QDs is that the colour of the 
particle changes with its size. The colour shifts towards blue, the smaller a QD 
becomes. In this telomerase activity protocol, the enzyme adds telomeric repeats to 
a DNA telomerase substrate, during which Cy5-dATPs is also incorporated. A 
newly synthesised DNA strand is then hybridised to a biotinylated capture probe, 
which allows for the binding of streptavidin-coated QDs. The QDs are then exited 
using light at 488nm wavelength, which causes fluorescence resonance energy 
transfer to the Cy5 receptor causing a fluorescent signal. Subsequently, the number 
of Cy5 can then be measured. The number of Cy5 is directly proportional to the 
length of the newly synthesised strand, as the Cy5 have consistent spacing between 
one another (due to the adenine residues found in telomeres). Telomerase activity 
can then be estimated by measuring the number of Cy5 through internal reflection 
fluorescence microscopy (Zhu et al., 2015). 
Metallic nanoparticles, for example gold nanoparticles (AuNPs) are another type of 
nanoparticle that have very interesting optical properties. Similar to QDs, AuNPs 
change the colour of the nanoparticle colloid solution based on their size and 
proximity to one another (Yarbakht and Nikkhah, 2016). The larger the AuNPs are 
in solution, the more the colour of the solution will shift towards the blue. On the 
other hand, the smaller the AuNPs in the solution, the more red shifted the colour 
of the solution becomes. If AuNPs become more aggregated, the colour of the 
solution also shifts towards blue. This aggregation can be achieved by adding salt 
to the AuNP solution, which cause the AuNPs to stop repulsing each other and 
begin to interact with one another. Due to these properties, one could very easily 
detect changes to the surface of the nanoparticle, as even a small change could result 
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in an observable colour change (Yarbakht and Nikkhah, 2016). This sensitivity as 
well as their ability to be easily functionalised to many different molecule, including 
thiolated DNA (by covalent bonding), could make AuNPs a very useful biosensor 
in detecting telomerase activity. If AuNPs could be coupled to a telomerase 
substrate (thiolated DNA), and salt is added to the solution, the colour of the 
solution would shift towards blue due to the close association of the particles. 
However, once telomerase is allowed to elongate the substrate, the steric hindrance 
caused by the elongated DNA, and possible secondary structure formation, will 
prevent the nanoparticle from closely associating. This would cause the colour of 
the solution to shift from blue to a more red colour (Wang et al., 2012) (Figure 1.6). 
This colour change could then be measured using UV-visual spectrophotometry 
(Zhang et al., 2012).  
Detecting telomerase activity using nanoparticles could prove very beneficial, as 
many steps found in conventional qPCR based methods could be eliminated. This 
includes the use of fluorescent probes and dyes, which can easily degrade, resulting 
in differing results from one experiment to another. This would also mitigate signal 
bleed through in 96-well plates, which can result in false positive results. 
Nanoparticles can reduce the time and cost involved in performing telomerase 
activity assays. For example, telomere extension has been detected in the protein 
extract of only 10 HeLa cells using AuNPs (Wang et al., 2012). Here Wang et. al 
confirmed telomerase inhibition, and therefore decreased elongation of the coupled 
(DNA) telomeric substrate, by TMPyP4 using their gold nanoparticle assay.  
 
 
 
 16 
 
 
 
Figure 1.6: Principles of a AuNP Based Telomerase Activity Assay (adapted from 
Wang et al., 2012). This illustration shows thioalted DNA (telomerase substrate) 
functionalised AuNPs. After functional telomerase is introduced to the nanoparticle 
solution, the substrate is elongated. This causes steric hindrance between the particles, 
causing them to disperse and causes a red shift in colour. The nanoparticle solution with 
the non-elongated substrate turns a blue colour due to the close association of the 
nanoparticles. 
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1.7 Aim: 
To improve on a nano-particle based detection method for telomerase activity and 
thereafter determine the effect of metformin on telomere dynamics in Oesophageal 
squamous carcinoma cells. 
 
1.7.2 Objectives: 
1) Determine the effects of metformin on cell proliferation by performing MTT 
assays. 
2) Determine hTERT mRNA expression in metformin treated and untreated cells 
by qPCR. 
3) Assess telomere length in metformin treated and untreated cells by qPCR. 
4) Assess telomerase activity in metformin treated and untreated cells by qPCR. 
5) Optimize chemical synthesis of spherical silver, platinum and gold nanoparticles 
by metal salt reduction under strict pH and temperature controls. 
6) Characterise nanoparticle size and morphology using UV spectrophotometry and 
electron microscopy. 
7) Functionalise nanoparticles with thiolated DNA and confirm successful 
functionalisation using electron microscopy. 
8) Detect telomerase activity on functionalised nanoparticles using UV 
spectrophotometry and compare it to conventional qPCR-based methods. 
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2 Materials and Methods: 
 
2.1 Cell Culture: 
2.1.1 Cell Culture Protocol: 
Oesophageal carcinoma cell lines; WHCO1, WHCO5 (Veale and Thornley, 1989), 
lung fibroblast; MRC5 (JACOBS et al., 1970), SNO (Bey et al., 1976), and human 
embryonic kidney cells; HEK293 (Graham et al., 1977), were cultured for this 
project. Professor R. Veale of the cell biology laboratory, at the University of the 
Witwatersrand, South Africa kindly provided the oesophageal cancer cells. Both 
WHCO1 and SNO cell lines were utilised in our previous work (Bernert, 2014). 
Inclusion of these cell lines was to verify the previously obtained data. HEK293 
cells were used to optimise procedures involving telomerase activity and hTERT 
expression, as these cells are known to display relatively high levels of hTERT and 
telomerase activity (Letsolo et al., 2010). The MRC5 cell line on the other hand was 
used as negative control as it expresses very little to no telomerase activity. Ethics 
approval was obtained from the Human Research Ethics Committee (Medical): 
reference number W-CJ-140804-1. 
Each of the five cell lines were cultured in 88% Dulbecco's Modified Eagle's 
Medium (DMEM) containing 10% Foetal Calf Serum, 1% Penicillin-Streptomycin 
and 1% L-Glutamine. The cells were kept in a 5% CO2, 37 °C humidified 
atmosphere to ensure that the pH of the system remained constant through the 
CO2/HCO3- buffering system and that the cells experienced maximum cell growth. 
Each cell culture flask was viewed under an inverted light microscope to monitor 
cell growth, cell detachment and to determine the level of confluency. After the 
cells reached approximately 80% confluency, they were harvested and passaged to 
prevent contact inhibition and therefore allow the cells to continue growing. To 
passage the cells, the cells were first detached from the flask through trypsin-EDTA 
treatment. The trypsin-EDTA was then inactivated by adding an equal volume of 
cell culture medium. The cells were then evenly passaged into multiple culture 
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flasks. The cells were treated with metformin while the untreated controls were 
cultured alongside the treated cells.  
After harvesting, some cells were cryopreserved to be used at a later stage. After 
trypsinisation the cells were harvested and centrifuged at low RPM (±200-400 g) 
for 10 minutes. The excess media was then removed and the pellet resuspended in 
a cryopreserving solution (15% Glycerol, 20% FCS, 65% DMEM). The vials were 
then kept at -20 ˚C overnight and then transferred to -80 ˚C or liquid nitrogen 
storage. When thawing the frozen cells, an initial high FCS concentration of 20% 
was used to provide extra nutrients for the cells. This was then stepped down to 
10% once the cells stabilised. 
2.1.2 Cell Quantification: 
To accurately quantify the number of cells in each flask once they reached 
confluency, a Neubauer haemocytometer was used. The cells needed to be 
quantified to ensure subsequent experiments and subcultures utilised consistent 
numbers of cells for reliable results. To distinguish between dead and live cells, the 
trypan blue stain was used. This stain is only taken up by dead cells, and is excluded 
by live cells, which leads to dead cells being stained blue under the microscope 
(Tran et al., 2011). This allows for easy quantification of unstained, live cells. The 
stained suspension of cells was diluted and a small sample added to the Neubauer 
haemocytometer. Live cells were then quantified, using the 16-square region of the 
haemocytometer, while utilising a light microscope. Thereafter, cell concentration, 
total number of cells as well as cell viability were calculated using the following 
formulas: 
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠
= 𝐶𝑒𝑙𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (
𝑐𝑒𝑙𝑙𝑠
𝑚𝑙
) 𝑥 𝑡𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 
𝐶𝑒𝑙𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (
𝑐𝑒𝑙𝑙𝑠
𝑚𝑙
) = 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 16 𝑠𝑞𝑢𝑎𝑟𝑒𝑠 𝑥 104 x dilution factor 
𝐶𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) = (
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑣𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠
) 𝑥 100 
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2.1.3 MTT Cell Viability Assay 
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay 
was used to determine cell viability. As the metformin treatment may affect cell 
proliferation and cell viability, this assay is very important to perform. The yellow 
MTT reagent is added to a plate of cells. Viable cells then reduce the reagent 
through cellular NAD(P)H-dependent oxido-reductases. This turns the MTT 
reagent into an insoluble formazan product, which is purple in colour, for 4 hours. 
The insoluble precipitate is then treated with a detergent and mixed until fully 
dissolved. After the formazan crystals are dissolved, the solution is read at 600 nm, 
using a spectrophotometer. The higher the amount of dissolved product, the higher 
the absorbance reading and therefore the more viable cells are present. This assay 
was performed in 96-well plates, where each well of a 96-well plate was seeded 
with 5000 cells. They were allowed to attach overnight and treatment commenced 
the following day. Each treatment as well as each control was done in triplicate. 
The controls included the no-cell control, no-MTT control, 100% dead cells (treated 
with 1% triton-x) as well as the untreated cell control. After the addition of the MTT 
reagent, the colour change was visualised using DMSO and an ELISA reader. The 
absorbance readings of the treated samples were then compared to those of the 
controls. 
 
2.2 Nucleic Acid Extraction: 
DNA and RNA were extracted from the cells using a modified phenol chloroform 
method as well as the Quick-RNA MiniPrep Kit (Zymo Research) respectively. In 
each case the cells were harvested and washed with PBS prior to pelleting them by 
centrifugation at 10000 g. The pellets were then washed with PBS to ensure no 
media remained. 
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2.2.1 DNA Extraction: 
A modified phenol chloroform extraction method was used to extract DNA from 
the various cell lines. The extraction buffer was made up of tris, glycerol, SDS and 
mercaptoethanol. This buffer was used to lyse the cells. Proteinase K was then 
added to digest the protein. To separate the cell debris and protein from the lysate 
containing the DNA, isopropanol and phenol chloroform were added to the cell 
lysate. The solution was then centrifuged at 10000 g for 5min at 4 ⁰C to pellet the 
cell debris, leaving the protein in the organic layer. Whilst the aqueous solution was 
then transferred to a new tube and mixed with ethanol. The solution was then 
centrifuged at 10000 g for 5min at 4 ⁰C again in order to precipitate the genomic 
DNA. Ethanol is then removed by air-drying the DNA pellet prior to resuspending 
in TE buffer. Both the amount as well as the purity of the DNA was then determined 
using the Thermo Scientific ND1000 NanoDrop spectrophotometer. After this, the 
DNA was resolved on a 1% agarose gel to determine integrity. 
 
2.2.2 RNA Extraction: 
RNA extraction was performed using the Quick-RNA Mini Prep Kit (Zymo 
Research). The cells were lysed and the protein degraded per the manufacturer's 
instructions. Cells were lysed using the cell lysate buffer. After a centrifugation step, 
the supernatant was pipetted into the “spin-away” filter before centrifuging again 
to remove the majority of the genomic DNA. Ethanol was added to the flow-through 
and the solution was added to the “Zymo-Spin IIICG Column”. After centrifugation, 
the flow-though was discarded and the column was treated with DNase for 15 
minutes to degrade any remaining genomic DNA. After multiple wash steps, the 
eluted RNA was stored in RNase-free water at -80 ˚C and the yield was determined 
using a NanoDrop (Thermo Scientific ND1000). As for the DNA, RNA integrity 
was verified by resolving the samples on a 1% agarose gel. 
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2.3 cDNA Synthesis: 
cDNA was synthesised using the ProtoScript First Strand cDNA synthesis Kit (New 
England BioLabs). The extracted, purified RNA sample was treated with DNase 
again to ensure that no genomic DNA remained in the sample. A short thermal cycle 
was then run, where the RNA was incubated at 25 ˚C for 5 minutes, then 42 ˚C for 
60 minutes. The reverse transcriptase was then inactivated at 80 ˚C for 5 minutes. 
The cDNA was then stored at -80 ˚C. Each sample was run alongside a no-template 
control, as well as a reverse transcriptase negative control to rule out contamination.  
 
2.4 Polymerase Chain Reaction (PCR) and Agarose Gel Electrophoresis: 
To assess the suitability of the DNA for PCR, MNS16A minisatellite as well as 
GAPDH and were amplified in all cell lines. 
 
Table 1: PCR Primers 
Table 1 illustrates PCR primers that were used in the study 
Primer 5'-3' Sequence Region Reference 
MNS16A  F-AGGATTCTGATCTCTGAAGGGTG 
R-TCTGCCTGAGGAAGGACGTATG 
MNS16A 
Minisatellite 
(Wang et al., 
2003) 
GAPDH  F-GTGGACCTGACCTGCCGTCT 
R-GGAGGAGTGGGTGTCGCTGT 
GAPDH (Zhang et 
al., 2012) 
17pseq1rev GAATCCACGGATTGCTTTGTGTAC STELA at 
17p 
telomere 
(Britt-
Compton et 
al., 2006) 
XpYpE TTGTCTCAGGGTCCTAGTG STELA at 
XpYp 
telomere 
(Baird et al., 
2003) 
Teltail TGCTCCGTGCATCTGGCATC Telorette tail (Baird et al., 
2003) 
Telorette2 TGCTCCGTGCATCTGGCATCTAACCCT End of 
telomere 
(Baird et al., 
2003) 
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For all PCR amplifications, KapaTaq Master Mix (Lasec) was used. This PCR 
master mix contains all the components needed for amplification, such as dNTPs, 
reaction buffer, magnesium chloride and taq-polymerase. The primers were added 
separately (Table 1). All amplifications were performed in a MJ Mini thermal cycler 
(BioRad) using the following thermal cycle: Initial denaturation was performed at 
95 ˚C for 2 minutes, followed by 35 cycles of denaturation (95˚C for 30 seconds), 
annealing (55 ˚C for GAPDH and 56 ˚C for the minisatellite for 30 seconds) and 
elongation (72 ˚C for 1 minute). A final elongation step was also performed at 72 
˚C for 2 minutes to ensure that all reactions had completed.  
After the PCR amplification, samples were resolved on agarose gels, using 
GRGreen (Inqaba Biotech) as a nucleic acid stain. GRGreen intercalates into DNA 
and creates a detectable fluoresces signal under UV light. The GAPDH sequence 
and the MNS16A minisatellite products were resolved on a 2.5% agarose gel. The 
gels were resolved at 80 V for 45 minutes to separate the DNA fragments by size. 
A DNA weight marker of known fragment lengths was used in order to determine 
the size of the amplified samples. The gels were then visualised under UV light.  
 
2.5 Quantitative Polymerase Chain Reaction (qPCR): 
2.5.1 Telomere Length: 
Telomere length was determined by using the EvaGreen qPCR System 
(GeneDireX) as per manufacturer’s instructions. EvaGreen is a dye, which 
fluoresces upon intercalating with DNA. The results obtained from the telomere 
length qPCR were then compared to that of the 36B4 reference gene to obtain a 
relative telomere length. The reference gene is a consistent size and can therefore 
be compared to the telomere length. Relative telomere length can then be 
determined. The following thermal cycle was used: Initial denaturation consisted 
of one cycle of 95 ˚C for 10 minutes. Amplification consisted of 45 cycles of 95 ˚C 
for 10 seconds, 56 ˚C and 58 ˚C (for telomere length and 36B4 respectively) for 10 
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seconds. The elongation step consisted of 72 ˚C for 10 seconds (where a single 
acquisition -where fluorescent is measured- was performed). 
 
2.5.2 hTERT mRNA Expression: 
hTERT mRNA Expression levels were determined by using the EvaGreen qPCR 
System (GeneDireX) as per manufacturer’s instructions. After cDNA synthesis, 
samples (including the reverse transcriptase minus controls) were amplified. The 
relative hTERT mRNA (expected size: 165 bp) expression levels for the different 
cell lines were determined using the mRNA expression levels of the reference genes 
(GAPDH and β-globin). The following thermal cycle was used: Initial denaturation 
consisted of one cycle of 95 ˚ C for 10 minutes. Amplification consisted of 45 cycles 
of 95 ˚C for 15 seconds, 60 ˚C (for GAPDH and β-globin) and 62 ˚C (for hTERT) 
for 30 seconds and 72 ˚ C for 10 seconds (where a single acquisition was performed). 
 
2.5.3 Telomerase Activity: 
The TRAPeze RT Telomerase Detection Kit (Merck-Millipore) was used to 
determine telomerase activity for all cell lines. qPCR amplifies a target DNA strand 
like conventional PCR, but is also able to simultaneously quantify the synthesis of 
the DNA strand. This is achieved using a sequence specific primer/DNA probe 
containing a fluorescent reporter as well as a quencher molecule. These reporter 
molecules fluoresce; however, due to the proximity of the quencher molecule, the 
fluorescent signal is suppressed. As the telomerase substrate is elongated by the 
telomerase enzyme, extracted from the cell lines, the probe causes a complimentary 
strand to be synthesised by taq polymerase. The incorporation of the probe causes 
the distance between the quencher and fluorophore to increase, creating a 
fluorescent signal. Therefore, the fluorescent signal is proportional to the amount 
of added telomeric repeats. Protein was extracted from cell pellets using 3-[(3-
Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) lysis buffer 
and the amount of protein being used was standardised to 0.2 mg/ml obtain reliable 
data (final concentration of 20 ng/µl). The HEK293 cells were used as a positive 
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control for telomerase activity (Letsolo et al., 2010). The following thermal cycle 
was used: Pre-incubation consisted of one cycle of 37 ˚C for 30 minutes and 95 ˚C 
for 2 minutes. Amplification consisted of 45 cycles of 95 ˚C for 30 seconds, 59 ˚C 
for 1 minute and 45 ˚C for 10 seconds (where a single acquisition, fluorescent data 
acquisition, was performed). 
 
2.6 STELA Protocol: 
The modified single telomere length analysis method (STELA) (Baird et al., 2003) 
consists of PCR amplification of telomeres extracted from cells. Since telomeres 
are highly repetitive, some additions and changes must first be made to the standard 
PCR reaction and Southern blotting procedure. Telomeres were amplified by a 
procedure where specific primers were first introduced to attach a recognisable 
fragment, to which the DNA polymerase of the PCR master mix can attach. The 
primers used in this experiment are described in Table 1 and below (Figure 2.1). 
Initial denaturation was performed at 95 ˚C for 2 minutes, followed by 35 cycles of 
denaturation (95 ˚C for 30 seconds), annealing (65 ˚C for XpYpE and 59 ˚C for 17p 
for 30 seconds) and elongation (72 ˚C for 5 minute). A final elongation step was 
also performed at 72 ˚C for 10 minutes to ensure that all reactions had completed. 
After the amplification of the telomeres, the PCR products were resolved on a 0.8% 
agarose gel at 120 V for 12 h. After the desired DNA fragments were separated, the 
DNA fragments within the gel were transferred onto a sheet of nitrocellulose. These 
fragments were then hybridised with a specific probe that is complimentary to the 
target sequence, which helps identify the fragment of interest. The agarose gel was 
placed on soaked filter paper in the presence of a transfer buffer, on top of which a 
nitrocellulose membrane was placed. More soaked filter paper was then placed on 
top of the nitrocellulose membrane. Weights were then added to the resulting stack 
to ensure that the DNA transfer proceeded evenly (Sambrook et al, 1989). During 
the transfer, the negatively charged DNA attaches to the positively charged 
membrane. The newly attached DNA was then fixed to the membrane by UV light 
exposure. The membrane was then treated using the TeloTAGGG kit (Roche). This 
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treatment allows for the visual detection of single telomeres on the membrane. The 
now attached single telomeres were then hybridised with a digoxigenin (DIG)-
labelled probe. After this, an alkaline phosphatase coupled anti-DIG antibody is 
bound to the DIG probe, which allows for the visualisation of the telomeres through 
the addition of a chemiluminescent substrate. This substrate reacts with alkaline 
phosphatase, resulting in a detectable colorimetric signal. This was then visualised 
using a ChemiDoc (BioRad). The standard STELA procedure utilises radio 
labelled-probes (Baird et al 2003). 
 
 
 
Figure 2.1: Graphic Representation of STELA Primer Binding Dynamics (modified 
from Baird et al., 2003). This diagram shows the primer binding locations of the STELA 
technique involved in the extension of the telomeres.  
 
2.7 Nanoparticle Synthesis: 
The synthesis and functionalisation of the nanoparticles were performed in the 
laboratory of and under the mentorship of Dr Sharon Moeno at the Department of 
Oral medicine, University of Witwatersrand. After synthesis, the nanoparticles 
were attached to synthetic thiolated DNA which, in this case, was a substrate for 
extracted telomerase to extend. 
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2.7.1 NP Synthesis Procedure: 
A concentrated 3:1 mixture of HCl:HNO3 was used to treat the glassware. This 
prevented nanoparticles (NPs) from attaching themselves to the sides of the 
glassware. Silver, Gold and Platinum NPs were synthesised by the metal salt 
reduction method (ions sourced from chloroauric acid, silver nitrate and 
chloroplatinic acid respectively), using sodium citrate as the reducing agent. 
Deionised water (50 ml) was added to a treated glass beaker. Metal salt was then 
added to the beaker to a concentration of 1mM. The beaker was then placed on a 
hotplate. The solution was stirred and allowed to heat up. Temperature is a vital 
factor in nanoparticle synthesis, so multiple were used to find the optimum 
temperature for each metal salt. Once the solution reached the desired temperature, 
sodium citrate was added until a colour change occurred. The amount and method 
of addition of the reducing agent also affects the formation of the NPs so multiple 
concentrations, and methods (ie. dropwise or rapid addition) were tested. The 
presence of a crimson colour indicated the formation of AuNPs within the desired 
size range, whereas brown and dark yellow indicated the synthesis of silver and 
platinum NPs respectively. The solution was then removed from the heat source 
and allowed to settle for a further 20 minutes with gentle stirring. The size and 
morphology was then verified using both scanning and transmission electron 
microscopy (SEM and TEM) as well as UV-visual spectrophotometry and Zetasizer 
measurements (light scattering). The NPs were then stored at room temperature in 
the dark. 
 
2.7.2 Platinum Nanoparticle Protein Functionalisation 
Platinum nanoparticles were first bound to lysozyme as a proof of concept that 
functionalisation of nanoparticles would result in a change in the UV-visible 
spectrum, as well as observe any changes under the SEM and TEM. Platinum 
nanoparticles were selected as they were thought to have a better chance to interact 
with the amide group found on the protein. The protein was added to 5 ml of diluted 
platinum nanoparticles (to a final concentration of 30 ng/µl). The nanoparticle-
protein solution was then incubated for 1h at room temperature while being stirred. 
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The absorbance of the protein-nanoparticle solution was quantified by 
spectrophotometry (UV-1800 Spectrophotometer (Shimadzu)) and the size and 
shape of particles were verified by SEM and TEM. 
 
2.7.3 AuNP DNA Functionalisation: 
All glassware was treated with 12M NaOH and washed with deionised water to 
prevent AuNPs from attaching to the glass, as this may affect the yield of the 
functionalised nanoparticles. Thiolated DNA (1 mM thiolated DNA: 5'-
HS(CH2)6TTTTTTTTTTAATCCGTCGAGCAGAGTT-3' (Wang et al., 2012)) 
was bound to both gold and platinum nanoparticles using a pH dependant sodium 
citrate method alongside a simple incubation. This was to improve on the method 
put forward by Wang et. al 2012, as the functionalisation reaction was labour 
intensive and time consuming, requiring constant adjustment and taking up to 40h 
to complete. For the sodium citrate method, the thiolated DNA was added to the 
nanoparticle solution to a final concentration of 2 µM and was mixed by inversion. 
The pH-buffered sodium citrate solution was then rapidly added to the mixture to a 
final concentration of 10 mM and was incubated for 20 minutes at room temperature. 
For the simple incubation method, the nanoparticle solution was once again brought 
to a final concentration of 2 µM of thiolated DNA. The solution was then mixed by 
inversion for 16h to allow the nanoparticles to attach to the thiolated DNA. The 
absorbance of the functionalised particles was read on the UV-vis 
spectrophotometer along with a control solution containing no DNA. The DNA 
modified AuNPs were then centrifuged at 13000rpm for 45 minutes to remove any 
excess DNA (Wang et al., 2012). The modified AuNPs were then resuspended in 
deionised water. 
 
2.7.4 AuNP Based Telomerase Activity Assay: 
The telomerase activity assay was based on the procedure by Wang et. al 2012, with 
the aim of increasing the speed at which the assay was performed as well as the 
ease of reading the results. In addition, Wang et. al 2012 performed their experiment 
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on Cervical cancer (HeLa), liver carcinoma (HepG2) and (breast cancer (MCF7), 
leukaemia (K562) cell lines. The aim was then to create a rapid, easy to use test 
which could measure telomerase activity in oesophageal cancer cell lines. The 
AuNP based telomerase activity assay was designed to be similar to a PCR reaction. 
A buffer was added to the DNA functionalised nanoparticle solution containing 
essential components needed by the telomerase enzyme to elongate the telomeric 
DNA substrate (20mM Tris-HCL at pH8.3, 6.3 mM KCL, 1 mM EGTA, 0.005% 
Tween-20, 0.1 mg/ml BSA, 1.5 mM MgCl2, 1 mM dNTPs) (Wang et al., 2012). 
Protein extract (extracted using CHAPS lysis buffer as described in 2.5.3), from 
HEK293 cells, was then added to the solution to a final concentration of 20 ng/µl, 
to keep it consistent with the qPCR telomerase activity assay. The solution was then 
incubated at 45 ˚C for up to 2h. This differed from the protocol designed by Wang 
et. al 2012; to ensure that the DNA was significantly elongated, 2h incubation was 
used instead of the 1h incubation and the temperature was changed from 30 ˚C to 
45 ˚C to keep it in line with the temperatures used in the qPCR based telomeres 
activity assay. After the extension reaction, the solution was transferred directly to 
a 96-well plate and the absorbance was read in an ELISA reader at 530 nm. This 
wavelength was chosen as it was determined to be the peak absorbance for the 
AuNP solution used in this experiment. This was an attempt to decrease the time 
and steps required to measure the absorbance compared to the method described by 
Wang et. al 2012, where they utilised a 400–750 nm spectra. The assay was then 
performed on SNO and WHCO5 cell lines due to the results obtained from the 
TRAPeze kit. Changes in the absorbance of the samples were then compared to the 
results obtained from the qPCR telomerase activity assay. A decrease in absorbance 
should indicate a decreased telomerase activity, as the nanoparticles associate closer 
together (Yarbakht and Nikkhah, 2016). This could then be compared to the 
decrease found with the TRAPeze qPCR kit. 
 
2.7.5 Electron Microscopy (SEM and TEM) 
Scanning electron microscopy (FEI Quanta FEG-SEM) and transmission electron 
microscopy (FEI Spirit 120 kV TEM) were used to determine the shape and size of 
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the synthesised gold, platinum and silver nanoparticles. Similarly, the lysozyme-
conjugated platinum nanoparticles as well as thiol-DNA conjugated gold 
nanoparticles were viewed under SEM and TEM. Sample preparation for the SEM 
included adding liquid nanoparticle solution to a carbon film attached to a sample 
stub. The sample was then dried to ensure that no liquid remains, as this could 
adversely affect the vacuum within the microscope. Sample preparation for the 
TEM included adding liquid nanoparticle solution to a 3 mm diameter copper grid 
coated with lacey carbon. The sample was then dried under a heat lamp until no 
moisture remained. The nanoparticles would then remain trapped on the lacey 
carbon. 
 
2.8 Data Analysis and Statistical Evaluation: 
The data collected from these experiments were analysed and evaluated in 
Microsoft Excel and GraphPad Prism (v6.05). Normalising as well as sorting in the 
obtained data was done in Microsoft Excel, whereas the statistical analysis was 
performed in GraphPad Prism, using ordinary one-way ANOVA at 95% confidence 
level between all sample groups.  
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3 Results: 
 
3.1 Cell Viability and Metformin Treatment: 
HEK293, MRC5, SNO, WHCO1 and WHCO5 cell lines were successfully cultured 
and treated with 5 and 10mM metformin for up to 72 h. Increased cell detachment 
was observed at these metformin concentrations after 48 and 72 h, compared to the 
untreated controls which had little to no detachment. The MTT assay was 
performed on each cell line to determine if metformin affected cell viability. Equal 
number of cells (5000) were added into each well of a 96-well plate. The cell lines 
were treated for 48 and 72 h with 5 and 10 mM metformin. No significant difference 
in cell viability was seen for the HEK293, MRC5, SNO and WHCO1 cell lines 
(Figure 3.1 A-D). The WHCO5 cell line (Figure 3.1 E) however showed a 
significant reduction in cell viability, compared to the untreated control, for both 
the 48 h and 72 h treatments. 
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Figure 3.1: Effects of Metformin on Cell Viability in HEK293, MRC5, SNO, 
WHCO1 and WHCO5 Cells. An MTT assay was performed on the HEK293 (A), MRC5 
(B), SNO (C) and WHCO1 (D) and WHCO5 (E) cell lines. Each cell line was treated with 
5 and 10 mM metformin for up to 72 h and compared to an untreated control at a 95% 
confidence level (where **P≤0.01 and ***P≤0.001).  
 
3.2 Single Telomere Length Analysis (STELA): 
The modified STELA was performed; however, the GR-Green nucleic acid stain 
produced no visible bands in the agarose gel after viewing it under UV light. 
Subsequently, no bands were visible, after the transfer to the nitrocellulose 
membrane. This may have been due to the nitrocellulose membrane being expired. 
Due to these complications as well as the high cost of the membranes, it was decided 
to determine telomere length using qPCR. 
 
3.3 Telomere Length: 
Telomere length was determined using qPCR. The telomere length reading was 
compared to that of the 36B4 reference gene to obtain a relative telomere length 
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(Pusceddu et al., 2015). This was unfortunately only successful in the SNO and 
WHCO5 cell lines, as the other samples would not amplify. The qPCR results were 
analysed in GraphPad Prism using ordinary one-way ANOVA at 95% confidence 
level to compare each data set. In the SNO cell line a significant decrease in 
telomere length was observed after the 72 h treatment at both the 5 and 10 mM 
metformin concentrations (Figure 3.2 A). The WHCO5 cell line on the other hand 
showed a decrease in the 48 h treatment for both 5 and 10 mM metformin 
concentration (Figure 3.2 B). It is also notable that there is a non-significant 
decrease in the 72 h 5 mM treatment, which could indicate that the 10 mM 72 h 
sample is an outlier.  
 
 
Figure 3.2: Effects of Metformin on Telomere Length in SNO and WHCO5 Cells. 
Telomere length was determined using qPCR on 5 and 10 mM metformin treated SNO (A) 
and WHCO5 (B) cell lines. This was then compared to the 36B4 reference gene (where 
**P≤0.05, **P≤0.01 and ***P≤0.001). 
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3.4 hTERT mRNA Expression: 
hTERT mRNA expression was determined by comparing the hTERT expression 
qPCR results to that of the reference gene; GAPDH. β-globin was also used as a 
reference gene; however, no amplification was obtained and could therefore not be 
compared to the expression results. Due to the expense of the qPCR reagents as 
well as the large number of samples that had to be analysed per cell line (each 
sample in triplicate for each of the two reference genes as well as the hTERT gene), 
the analysis was performed on the WHCO5 cell line only (Figure 3.3). This was 
due to the cell line showing both a significant decrease in telomere length as well 
as cell viability due to the metformin treatment. qPCR analysis showed no 
significant difference in hTERT mRNA expression for the treated and untreated 
WHCO5 samples 
 
 
Figure 3.3: Effects of Metformin on hTERT mRNA Expression in WHCO5 Cells. 
mRNA expression was determined in the WHCO5 cell line using GAPDH as a reference 
gene. No significant difference was seen in both the 48 and 72 h treatments compared to 
the untreated control. 
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3.5 Telomerase Activity by qPCR: 
The TRAPeze RT Telomerase Detection Kit (Merc) was used to determine 
telomerase activity by qPCR. Telomerase activity was measured in all cell lines, 
using the HEK293 cells as a positive control and the MRC5 cell line as a negative 
control. Statistical analysis was performed through GraphPad Prism, using ordinary 
one-way ANOVA at 95% confidence level to compare the metformin treated and 
untreated samples. Only the 48 h readings were obtained for both the WHCO1 and 
WHCO5 cell lines, as no amplification took place at the 72 h timepoint (including 
the untreated control). A significant reduction in telomerase activity was seen in the 
HEK293 (positive control), SNO and WHCO5 cell lines (Figure 3.4 A, C, E) with 
a downward trend seen in the WHCO1 cell line (Figure 3.4 D). The MRC5 cell line 
(Figure 3.5 B) showed little to no telomerase activity, which was expected from a 
negative control, however the 72 h untreated MRC5 sample seems to be an outlier. 
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Figure 3.4: Effects of Metformin on Telomerase Activity in HEK293, MRC5, SNO, 
WHCO1 and WHCO5 Cells. Telomerase activity was determined in the HEK293 
(A), MRC5 (B), SNO (C) and WHCO1 (D) and WHCO5 (E) cell lines. Each cell line was 
treated with 5 and 10 mM metformin for up to 72 h. Statistics were performed at a 95% 
confidence level (where ***P≤0.001). The MRC5 cell line (B- negative telomerase control) 
had very low telomerase activity. 
 
3.5 Metallic Nanoparticle Synthesis: 
Spherical nanoparticles were synthesised using the chemical hydrothermal method 
by metal salt reduction. Silver nitrate, chloroplatinic acid and chloroauric acid were 
reduced using sodium citrate to synthesise silver, platinum and gold nanoparticles, 
respectively. Size and morphology of the nanoparticle were determined using UV-
Vis spectrophotometry (Figure 3.5, 3.7), SEM and TEM (Figure 3.6, 3.8, 3.11). 
ImageJ analysis was performed on the TEM images to determine the average 
diameter of the spherical nanoparticles. In all three cases, synthesis was successful, 
however only the gold nanoparticles proved to be of the correct size and uniform 
morphology needed for most downstream applications (Figure 3.11). 
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3.5.1 Silver Nanoparticle Synthesis: 
Silver nanoparticles were successfully synthesised and produced a solution with a 
brown colour. The spectrophotometry results show a large size range for the silver 
nanoparticles, as indicated by the wide peak (Figure 3.5). This was further 
confirmed by the TEM results (Figure 3.6 B), where nano-rods and nano-triangles 
of varying sizes were present alongside the 50 nm diameter spherical nanoparticles. 
This large range in particle shapes and sizes would indicate that these silver 
nanoparticle solutions are not suitable for downstream applications. 
 
 
Figure 3.5: Spectrophotogram of a Silver Nanoparticle Solution. The absorbance of 
the silver nanoparticle solution was measured in the range of 200-800 nm. The 
spectrophotogram shows one wide peak at 450nm which has shoulder at 340 nm. This is 
indicative of a large size range of the silver nanoparticles. 
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Figure 3.6: Synthesis of Silver Nanoparticles. SEM and TEM images of the silver 
nanoparticles were taken. The SEM image (A) showed clusters of nanoparticles. However, 
the TEM image (B) showed the presence of nano-rods and nano-triangles in the 
nanoparticle solution as well as an average spherical particle size of 50 nm. 
 
3.5.2 Platinum Nanoparticle Synthesis: 
Platinum nanoparticles were synthesised, producing a solution with a dark yellow 
colour. The Spectrophotogram (Figure 3.7) showed no distinct peak, making it 
difficult to determine the uniformity of the platinum nanoparticles. Indeed, it was 
thought that synthesis was not successful, however SEM and TEM images (Figure 
3.8) confirmed the presence of nanoparticles. The TEM image (Figure 3.8 B) 
showed that the particles were very closely associated and therefore a more accurate 
ImageJ analysis was not possible.  
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Figure 3.7: Spectrophotogram of a Platinum Nanoparticle Solution. The absorbance 
of the solution was measured in the range of 200-800nm. This spectrophotogram showed 
no distinct peaks. 
 
 
Figure 3.8: Synthesis of Platinum Nanoparticles. Platinum Nanoparticles were 
successfully visualised under SEM (A) and TEM (B). The particles were clearly visible as 
large spheres under SEM, however under TEM the particles were very difficult to observe. 
Under TEM it was seen that the particles were approximately 50 nm in diameter. 
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3.5.3 Gold Nanoparticle Synthesis: 
AuNPs were successfully synthesised and produced a solution with a distinct red 
colour. The size of AuNPs was also very easy to control, with distinct colour 
changes accompanying the change in size (Figure 3.9). If the reducing agent was 
added slowly to the synthesis reaction at 65 ˚C, the colour of the solution turned 
from red to purple and then blue. The gold tinge in the far-left vial (Figure 3.9) 
indicates the presence of gold macromolecules/ aggregation. The 
spectrophotometer readings (Figure 3.10) showed a distinct thin peak, indicating 
very uniform particle size distribution. This was also confirmed with the TEM 
images (Figure 3.11 B), where after ImageJ analysis it was found that the average 
diameter of the particles of the red solution was 13 nm. The narrow size distribution 
as well as the distinct colour differences due to particle size made AuNPs the natural 
choice for the subsequent DNA functionalisation. 
 
 
Figure 3.9: Effects of AuNP Size on Nanoparticle Solution Colour. AuNP synthesis 
yielded very distinct colour differences as the size of the nanoparticles was 
increased. As the nanoparticles became larger, the solution underwent a blue shift. A gold 
tinge is also present in the far-left vial. 
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Figure 3.10: Spectrophotogram of a Gold Nanoparticle Solution. The absorbance of 
the solution was measured in the range of 200-800 nm. A distinct, thin peak can be seen at 
530 nm, which may indicate a high degree of uniformity amongst the AuNPs. 
 
 
Figure 3.11: Successful Synthesis of AuNPs. The presence of AuNPs was confirmed 
through SEM (A) and TEM (B). A greater magnification was not possible in the SEM 
images, due to the resolution of the microscope as well as the small size of the nanoparticles. 
Under TEM, the nanoparticles were clearly visible and dispersed. The solution consisted 
mainly of nano-spheres but few nano-triangles were present. ImageJ analysis of the TEM 
images confirmed that the average diameter of the AuNPs was 13 nm.  
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3.6 Protein Functionalisation of Platinum Nanoparticles: 
Platinum nanoparticles were functionalised with lysozyme to determine the effects 
of surface modification of nanoparticles. Platinum was used due the hope that the 
thiol groups present in the protein would associate strongly with platinum. The 
unmodified platinum nanoparticles looked very similar to the lysozyme modified 
particles, however a possible protein coating was observed (Figure 3.12). Due to 
the difficulty of viewing platinum nanoparticles under TEM, as well as the lack of 
a colour change, it was decided to continue the experiment with AuNPs. 
 
 
Figure 3.12: Protein Functionalisation of Platinum Nanoparticles. Platinum 
nanoparticles were functionalised with lysozyme. The un-modified control (A) was very 
similar to the protein coupled nanoparticles (B). However, some particles seemed to have 
a coating which may be evidence of the protein attaching to the nanoparticles. 
 
3.7 Thiol-DNA Functionalisation of Gold Nanoparticles: 
AuNPs were used for subsequent experiments, due to their easily visible colour 
change in solution as well as their uniformity. Thiolated DNA was coupled to the 
AuNPs via the simple 16h incubation method. This was preferred, as the sodium 
citrate buffer method caused rapid aggregation after which the nanoparticles would 
not re-disperse. DNA coupled AuNPs were then characterised using TEM as well 
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as spectrophotometry. The spectrophotometer results (Figure 3.13 A) showed a 
distinct shift after functionalisation. The lowering of the peak could indicate that 
the particles are more closely associated. This shift is consistent with an increase in 
size of the modified nanoparticles. (Figure 3.13 B) showed the colour change that 
occurred due to the functionalisation. This blue shift in colour is once again 
consistent with larger (or more closely associated) AuNPs. TEM images (Figure 
3.14) show a distinct halo around modified AuNPs (B), which cannot be seen in the 
unmodified particles (A). This halo seems to indicate the presence of DNA on the 
surface of the AuNPs. Using a Zetasizer (Figure 3.15), the size of the nanoparticles 
could be determined using light scattering. (A) showed a 40 nm peak suggesting 
that the average particle size of the AuNP control is 40 nm in diameter. The DNA 
functionalised sample (B) had two peaks at 40 and 110 nm, suggesting that there 
are two particle sizes predominantly found in the solution this may be due to some 
unfunctionalized particles. The sample containing the DNA functionalised AuNPs 
and the HEK293 protein extract (C) had the two peak sizes (at 40 nm and 110 nm) 
seen in (B), however there is evidence of massive aggregation (peak from 1000 nm 
to 6000 nm). 
 
Figure 3.13: Effects of DNA Functionalisation on AuNP Spectrophotogram and 
Solution Colour. The spectrophotogram of the modified and unmodified nanoparticles 
(A), where black indicates the control and red indicates the DNA coupled AuNPs, shows a 
distinct shift in the single peak from 530 nm to 550 nm as well as a lowering of the peak. 
The red graph also has an additional peak at 260 nm which represents the DNA. (B) shows 
the colour change that occurred after functionalisation. 
 44 
 
 
 
Figure 3.14: Transmission Electron Microscopy Analysis of DNA Functionalised 
AuNPs. TEM images were taken of the functionalised (B) and non-functionalised (A) 
AuNPs. A clear halo was seen around DNA modified AuNPs (B), which could not be seen 
in the unmodified control (A). (Larger AuNPs, approximately 50 nm in diameter were used 
to show the halo, as the larger halo was more easily distinguishable). 
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Figure 3.15: Zetasizer Analysis of AuNP Size Distribution using Light Scattering. 
Zetasizer measurements were taken on the AuNP solution before and after DNA 
functionalisation. The height of the peak signifies the amount of the standard size of the 
particles and the width of the peak shows the size deviation from the standard. The 
unmodified AuNP solution (A) shows a single peak at 40 nm and (B) shows the results of 
the DNA modified AuNPs, where two distinct peaks, one at 40 nm (as in A) and one at 110 
nm can be seen. (C) shows the results of DNA modified AuNPs after the addition of the 
HEK293 protein extract. The two peak sizes (at 40 nm and 110 nm) are still present, 
however there is evidence of massive aggregation (peak from 1000 nm to 6000 nm). 
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3.8 Gold Nanoparticles Based Telomerase Activity Assay: 
The AuNP based telomerase activity assay was performed similarly to a PCR 
reaction and the colour change was measured using a spectrophotometer. Thereafter 
the solutions were viewed under TEM. Although a distinct colour change was seen 
compared to a negative control (Figure 3.16 C and D), the sample that was allowed 
to elongate the attached DNA (D) did not show as much aggregation as in (C). This 
was further confirmed by TEM images (Figure 3.17), where (C) showed massive 
aggregation compared to (D). this could signify telomerase activity. Once again, 
this confirms the light blue colour of the sample solution (Figure 3.16-D). The 
particles in (B) showed slightly more association, which could account for its more 
purple colour (Figure 3.16-B). After performing the reaction, absorbance readings 
did not find any significant difference between metformin treated and untreated 
samples (Figure 3.18) although a difference could previously be seen between 
elongated and non-elongated samples. Therefore, further optimisation of the assay 
is required to determine these more subtle differences. 
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Figure 3.16: Modified AuNP based Telomerase Activity Assay Colour Change. 
This image shows the colour change of the nanoparticle solution after performing the AuNP 
assay. (A) contains unmodified AuNPs as well as the reaction buffer necessary for the 
telomere extension reaction and has a red colour. (B) contains DNA modified AuNPs as 
well as the reaction buffer and has a light purple colour. (C) contains the DNA modified 
AuNPs, reaction buffer and protein extract, where aggregation can easily be seen at the 
bottom of the tube. (D) contains the same components as C, however the extension reaction 
has been allowed to proceed. This Sample has a light blue colour and very little aggregation 
is present. 
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Figure 3.17: Transmission Electron Microscopy Analysis of the Modified AuNP 
Based Telomerase Activity Assay. This image shows unmodified AuNPs (A), which 
are largely dispersed. The DNA functionalised AuNPs (B) show increased association with 
one another. (C) shows DNA modified AuNPs in the presence of a protein extract. Here 
high amounts of aggregation can be seen. (D) on the other hand, shows the same sample as 
seen in C, however the telomere extension reaction was performed. This sample still shows 
signs of aggregation, but far less that that seen in (C).  
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Figure 3.18: Relative Telomerase Activity of the AuNP Based Telomerase Activity 
Assay in SNO and WHCO5 Cells. After the telomere extension reaction, the absorbance 
of the nanoparticle solutions containing protein extracts from metformin treated SNO (A) 
and WHCO5 (B) cell lines was obtained. No significant difference could be seen between 
treated and untreated samples within the cell lines.  
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4 Discussion: 
 
4.1 Cell Viability: 
In this study, metformin was found to affect telomere dynamics. It was clear that 
cells cultured in the presence of the drug had higher amounts of detachment 
compared to that of the untreated controls. This was assumed to be the cause of 
decreased cell viability due to the treatment. After performing MTT cell viability 
assays however, it was found that HEK293, MRC5, SNO and WHCO1 cell lines 
did not have a significant decrease in cell viability (Figure 3.1). This would suggest 
that the detachment is not necessarily a sign of cell death, but may be due to 
metformin interfering with cell-surface adhesion proteins such as Integrin-linked 
Kinase (ILK) (Vespa et al., 2005). In fact, it has been shown that metformin can 
decrease ILK gene expression through the indirect regulation of Sp1 and AP-2α 
(Activating Protein 2 α) protein expressions (Hahn et al., 2014). The number of 
viable cells could be determined using a trypan blue assay on the detached cells to 
determine if this is indeed the case. The WHCO5 cell line did show a significant 
decrease in cell viability in both the 48 and 72 h treatments whereas the WHCO1 
cell line did not (Figure 3.1). The reason for this is currently unknown and would 
require further research. Since both WHCO1 and WHCO5 cell lines possess wild 
type p53 (Fanucchi and Veale, 2009), it could be possible that due to a mutation, 
metformin is unable to activate the p53 tumour suppressor within the WHCO1 cell 
line.  
 
4.2 Metformin Decreases Telomere Length: 
Telomere length has been associated with cell viability (Sahin and Depinho, 2010) 
and is therefore an important factor to consider after treatment. Metformin was also 
shown to significantly decrease telomere length in the WHCO5 cell line after 48 h 
but not after 72 h, although a downward trend was visible in the 5 mM 72 h 
treatment. Whereas the SNO cell line showed a significant decrease in telomere 
length after 72 h (Figure 3.2). This was unexpected, as the treatment was only 
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performed for up to 72 h and should therefore not have resulted in significantly 
reduced telomere length. An alternate explanation may be that the results are due to 
the increased stress of the treatment, resulting in a loss of telomere integrity. The 
literature has shown that metformin indeed increases oxidative stress in 
neuroblastoma cells (Picone et al., 2015) and white adipocytes (Anedda et al., 2008). 
A decrease in telomere length due to oxidative stress has also previously been 
reported due to a variety of factors, including lifestyle variables such as smoking 
(Babizhayev et al., 2011) and lifestyle diseases such as type 2 diabetes (Sampson et 
al., 2006). 
 
4.3 Metformin Reduces Telomerase Activity: 
Metformin significantly decreased telomerase activity in HEK293, WHCO5 and 
SNO cells, and caused a downward trend in the WHCO1 cell line (Figure 3.4). The 
MRC5 cell line had very low/ undetectable levels of telomerase activity, which is 
consistent with the literature, as normal somatic cell lines generally express low 
amounts of telomerase (Kim et al., 1994). This coupled with the fact that metformin 
does not influence telomerase at the DNA level (Bernert, 2014) and that hTERT 
mRNA expression was not influenced by the metformin treatment in the WHCO5 
cell line (Figure 3.3), which is in contrast to previous findings in the literature where 
metformin decreased hTERT mRNA expression in endometrial cancer (Hanna et 
al., 2012), seems to suggest that metformin may acts on the protein level in 
oesophageal cancer. It is however not known if it is a direct association to hTERT 
or the telomerase enzyme as a whole. Despite this, metformin significantly 
decreased telomerase activity and may therefore be a suitable treatment option, in 
conjunction with conventional therapies, to treat oesophageal cancer and perhaps 
other cancers that utilise increased telomerase activity to bypass senescence.  
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4.4 Successful Nanoparticle Synthesis: 
Silver, platinum and gold nanoparticles were successfully synthesised using 
chemical hydrothermal metal salt reduction. Absorbance spectra and SEM and 
TEM images of all samples were taken to determine size distribution of the particles. 
The spectrophotogram of the silver nanoparticles (Figure 3.5) showed a wide peak, 
which suggested that the synthesised nanoparticles had a large size range. This was 
later confirmed by the electron microscopy of the brown nanoparticle solution, 
where the TEM image (Figure 3.6 B) showed the presence of nano-triangles, nano-
rods and spherical nanoparticles. The spectrophotogram of the platinum 
nanoparticles (Figure 3.7) on the other hand had no discernible peak, which made 
it impossible to determine the size distribution and it was thought that the synthesis 
had failed. The colour of the solution did change to a dark yellow however and the 
SEM and TEM images (Figure 3.8) confirmed platinum nanoparticle synthesis, 
however the particles were difficult to distinguish. This spectrophotogram is 
however consistent with the literature for platinum nanoparticles. The gold 
nanoparticles were very easily synthesised, and their sizes were easily controlled. 
The solutions also had very clear colour changes as the nanoparticles increased in 
size (Figure 3.9). The spectrophotogram of the gold nanoparticles (Figure 3.10) 
showed a relatively slim peak, which is consistent with uniform nanoparticle size. 
This was confirmed using TEM (Figure 3.11 B), where the nanoparticles had a very 
uniform morphology. Mostly nano-spheres were found, with very few nano-
triangles and no nano-rods present. After an ImageJ analysis, it was found that the 
average size of the particles was 13 nm.  
 
4.5 Successful Protein Functionalisation of Platinum Nanoparticles: 
Before coupling the nanoparticles to the synthetic telomeric DNA, a proof-of-
concept experiment was performed to show that the colour of the nanoparticle 
solution would change due to the presence of attached molecules. Platinum 
nanoparticles were functionalised with lysozyme, as it was thought that the 
platinum would more easily associate with the amide groups present in the protein. 
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There was no visible colour change after the protein functionalisation, however 
TEM images did show coat was present on the nanoparticles compared to the 
control (Figure 3.12 B). This coat may be the protein associating with the 
nanoparticles, unfortunately the platinum nanoparticles were difficult to distinguish 
under TEM. Due to this, as well as the difficulty in seeing a colour change, gold 
nanoparticles were used for the DNA functionalisation experiments. 
 
4.6 Successful DNA Functionalisation of AuNPs: 
Due to the success of the previous protein functionalisation experiment, DNA 
functionalisation was performed. For the DNA functionalisation experiments, the 
small 13 nm diameter red AuNP solution was used, as the colour of the solution 
would shift towards blue if the particles would move further apart from one another. 
After functionalisation, the colour of the solution visibly turned to a more purple 
colour and the spectrophotogram showed both a shift in the peak as well as the 
presence of the DNA at 260 nm (Figure 3.13). This seemed to show that the AuNPs 
were either acting as larger nanoparticles due to the presence of the DNA on their 
surface or that they were more closely associated. This close association could 
however be due to the DNA on the particles directly binding to one another (Hill et 
al., 2009). It was confirmed, using TEM (Figure 3.14), that a distinct halo was 
present surrounding the DNA coupled AuNPs but not the untreated control, which 
seems to indicate that the nanoparticles do indeed act as larger particles when 
functionalised. Light scattering was then performed on the samples using a 
Zetasizer to determine any change in the relative size of the nanoparticles (Figure 
3.15). The 13 nm diameter AuNPs (determined using TEM) gave a reading of 40 
nm. This is due to the Zetasizer measuring the hydrodynamic size of the particles, 
where it takes the surrounding liquid molecules into consideration. This 
measurement is often larger than the actual size of the particle. The DNA 
functionalised sample showed a second peak at 110 nm. This suggests that not all 
the nanoparticles were functionalised and those that were showed an increased 
hydrodynamic size. A third solution was measured, containing functionalised 
nanoparticles as well as protein extract, to determine the effects of the proteins on 
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the size of the functionalised nanoparticles. This third sample showed both the 40 
nm and 110 nm peaks as well as a very broad peak towards the micron size range, 
indicating aggregation. Light scattering showed that there was a definite change in 
the diameter of the nanoparticles after the addition of the thiolated DNA, 
confirming DNA functionalisation.  
 
4.7 AuNP Based Telomerase Activity Assay: 
After successful DNA functionalisation, the AuNP based telomerase activity assay 
was performed. As the extracted telomerase, in the protein extract, elongated the 
synthetic telomeres. It was thought that the nanoparticles would act as larger AuNPs 
due to the increased diameter of the nanoparticles and the elongated DNA and 
therefore cause a blue shift in the colour of the solution. There was a distinct colour 
change from the purple of the DNA-functionalised AuNP solution (Figure 3.16 B) 
to a light blue after the addition of the protein extract (Figure 3.16 C). This was then 
followed by aggregation. In the sample where the attached DNA was elongated 
however, there was significantly less aggregation and the dark blue colour was 
easily visible (Figure 3.16 D). This would suggest that the elongated DNA serves 
not only to increase the distance between particles, thereby treating them as larger 
particles, and causing a colour shift, but also to resist aggregation of the particles. 
This resistance to aggregation should then be measurable by spectrophotometry. 
This resistance to aggregation was then confirmed using TEM (Figure 3.17). The 
unmodified AuNPs were very dispersed (Figure 3.17 A), and only slightly more 
association between particles in the DNA modified AuNP sample was observed 
(Figure 3.17 B). The sample containing both DNA functionalised AuNPs and 
protein extract, predictably showed massive aggregation (Figure 3.17 C). The 
sample where the DNA was elongated by telomerase (Figure 3.17 D) showed 
significantly less aggregation than the non-elongated sample (Figure 3.17 C). For 
the metformin treatments, SNO and WHCO5 protein extracts were then used to 
elongate the telomeric substrate using a short PCR step. Absorbance readings were 
then taken of the resulting nanoparticle solutions (Figure 3.18). Unfortunately, both 
the SNO and WHCO5 cell lines showed no significant difference between the 
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untreated and treated samples. This contrasts with the telomerase activity data 
obtained using qPCR, where both cell lines exhibited a decrease in telomerase 
activity. Although a difference was seen between non-elongated samples and 
elongated samples, the assay was not sensitive enough to differentiate between 
treated and untreated samples of the same cell line. This may be partially due to the 
presence of unmodified AuNPs, as seen by the light scattering results, causing 
additional aggregation. However, since TEM images confirmed a difference in 
aggregation despite the presence of unmodified AuNPs, the lack of significant 
results is likely due to the measurement technique not being sensitive enough. 
 
4.8 Conclusion: 
In conclusion, the MTT assay showed that only the WHCO5 cell line had a 
significant decrease in cell viability despite large amounts of cell detachment in the 
other cell lines. Cell detachment may therefore not be an indicator of cell viability 
after metformin treatment. Metformin also affected telomere length but not hTERT 
mRNA expression, which is in contrast to previous findings where metformin 
decreased hTERT mRNA expression in endometrial cancer (Hanna et al., 2012). 
Metformin significantly reduced telomeres activity in HEK293, SNO, WHCO5 cell 
lines and caused a downward trend in the WHCO1 cell line. This could therefore 
potentially be used in conjunction with conventional anti-cancer treatments for a 
more effective method of treating cancers that use increased telomerase activity to 
bypass senescence. AuNPs were successfully synthesised and functionalised with 
thiolated DNA (telomerase substrate). The nanoparticles were then characterised 
and visualised using spectrophotometry and electron microscopy. The AuNP based 
telomerase activity assay was then performed on the SNO and WHCO5 cell lines, 
but treated samples did not show any significant difference to the untreated samples. 
This assay does however have great potential in becoming a cheaper, faster 
alternative to that of the conventional qPCR based techniques once further 
optimised. 
 
 56 
 
4.9 Future Work: 
Future work will include an alternative to the MTT cell viability assay, possibly the 
alamarBlue assay, to confirm the results obtained. Trypan blue assays will also be 
performed on detached cells to determine if the cells are indeed dead or simply 
detaching due to the metformin treatment. Western blots will also be performed to 
determine the total hTERT protein levels in the cell lines. Protein association 
studies can also be done to determine if metformin directly binds to hTERT, hTERC 
or the larger telomerase enzyme. The AuNP telomerase activity assay can also be 
improved by optimising the DNA functionalisation step further to reduce the 
number of non-functionalised nanoparticles within the solution. It would also be 
beneficial to scale up the AuNP experiment (from 50 µl to 300 µl), to have a larger 
volume of sample to test. This would make it possible to test one sample using 
multiple techniques such as light scattering and UV-spectroscopy, which are more 
sensitive than absorption spectrophotometry. 
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6 Appendix: 
 
6.1 Materials used: 
Table 1A: Cell Culture Reagents 
Product Supplier 
Cell Culture Flasks (75cm) Sigma Aldrich 
DMEM Sigma Aldrich 
L-Glutamine Sigma Aldrich 
Penicillin-Streptomycin Celtic 
Foetal Calf Serum Celtic 
Trypsin/EDTA Celtic 
Metformin Sigma Aldrich 
MTT Sigma Aldrich 
 
Table 2A: DNA/RNA Reagents 
Product Supplier 
Quick-RNA Mini Prep Kit  Zymo Research 
ProtoScript First Strand cDNA synthesis Kit 
New England 
BioLabs 
Tris Signa Aldrich 
Glycerol Signa Aldrich 
SDS Signa Aldrich 
Mercaptoethanol Signa Aldrich 
Proteinase K Inqaba Biotech 
Ethanol Signa Aldrich 
Isopropanol Signa Aldrich 
Phenol–chloroform Signa Aldrich 
 
Table 3A: PCR/qPCR Reagents and Primers 
Product Supplier 
MNS16A Primers Inqaba Biotech 
GAPDH Primers Inqaba Biotech 
KAPA Taq Lasec 
GRGreen Inqaba Biotech 
EvaGreen GeneDireX 
SeaKem® LE Agarose Lonza 
(10x) TBE Buffer Sigma Aldrich 
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(10x) TAE Buffer Sigma Aldrich 
1kb DNA Ladder Separations 
TRAPeze RT Telomerase Detection Kit 
Merck-
Millipore 
 
Table 4A: STELA Reagents and Primers 
Product Supplier 
TeloTAGGG kit UTI Pharma 
Nitrocellulose Membrane Separations 
Primer: 17pseq1rev Inqaba Biotech 
Primer: XpYpE Inqaba Biotech 
Primer: Teltail Inqaba Biotech 
Primer: Telorette2 Inqaba Biotech 
 
Table 5A: AuNP Synthesis/Functionalisation 
Product Supplier 
Chloroauric acid Sigma Aldrich 
Citric acid Sigma Aldrich 
Thiolated Oligonucleotides (Telomerase Substrate) Inqaba Biotech 
 
 
6.2 Buffer Compositions: 
Table 6A: DNA Extraction Buffer: 
Compound Final Percentage 
Tris-HCL (pH 6.8) 45 % (0.2 M) 
Glycerol 45 % 
SDS 5 % 
Mercaptoethanol 5 % 
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Table 7A: Nanoparticle Assay Telomere Elongation Buffer: 
Compound Final Concentration 
Tris-HCL (pH 8.3) 20 mM 
KCl 6.3 mM 
EGTA 1 mM 
Tween-20 0.005 % 
BSA 0.1 mM 
MgCL 1.5 mM 
dNTPs 1 mM 
 
Table 8A: Cell Culture Medium: 
Compound Percentage 
Dulbecco's Modified 
Eagle's Medium 
88 % 
Foetal Calf Serum 10 % 
Penicillin-Streptomycin 1 % 
L-Glutamine 1 % 
 
6.3 Equipment Used: 
Table 9A: Equipment Used: 
Equipment Manufacturer 
Neubauer haemocytometer Sigma Aldrich 
1-14 Microcentrifuge Sigma Aldrich 
ND1000 NanoDrop spectrophotometer Thermo Scientific 
MJ Mini thermal cycler BioRad 
ChemiDoc BioRad 
LightCycler 480 (qPCR) Roche 
UV-1800 Spectrophotometer Shimadzu 
FEI Quanta FEG-SEM Fei 
FEI Spirit 120 kV TEM Fei 
Zetasizer Malvern 
 
